IRETA’s Executive Director was quoted in a recent article published by KFF Health News: “Maker of Device To Treat Addiction Withdrawal Seeks Counties’ Opioid Settlement Cash”.
The article explores the rapid consumption of opioid settlement dollars by a manufacturer of a device designed to treat opioid withdrawal. The reporting also highlights questions raised by researchers and advocates about the evidence supporting these devices and how opioid settlement funds are being allocated, noting broader concerns about investing in emerging or less-established interventions.
The article is part of ongoing coverage examining how opioid settlement funds are being used at the state and local levels.
Dr. Hulsey was quoted in relation to the distinction that these devices were FDA-cleared to treat opioid withdrawal symptoms and not opioid use disorder. “The term ‘treatment’ becomes confusing,” Hulsey said. “These devices were cleared to treat opioid withdrawal symptoms, not to treat an opioid use disorder.”
Check out IRETA’s Neuromodulation Devices for Opioid Withdrawal FAQ that was cited in the article: https://ireta.org/resources/neuromodfaq/
